Zymeworks Inc. (ZYME)
ZYME Stock Price Chart
Explore Zymeworks Inc. interactive price chart. Choose custom timeframes to analyze ZYME price movements and trends.
ZYME Company Profile
Discover essential business fundamentals and corporate details for Zymeworks Inc. (ZYME) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Apr 2017
Employees
299.00
Website
https://www.zymeworks.comCEO
Kenneth H. Galbraith
Description
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
ZYME Financial Timeline
Browse a chronological timeline of Zymeworks Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.45, while revenue estimate is $17.20m.
Earnings released on 7 May 2026
EPS came in at -$0.59 falling short of the estimated -$0.10 by -490.00%, while revenue for the quarter reached $2.41m , missing expectations by -90.12%.
Earnings released on 2 Mar 2026
EPS came in at -$0.55 falling short of the estimated -$0.35 by -57.14%, while revenue for the quarter reached $2.52m , missing expectations by -86.93%.
Earnings released on 6 Nov 2025
EPS came in at -$0.26 surpassing the estimated -$0.30 by +13.33%, while revenue for the quarter reached $27.61m , beating expectations by +41.69%.
Earnings released on 7 Aug 2025
EPS came in at $0.03 surpassing the estimated -$0.52 by +105.77%, while revenue for the quarter reached $48.73m , beating expectations by +89.26%.
Earnings released on 8 May 2025
EPS came in at -$0.30 surpassing the estimated -$0.45 by +33.33%, while revenue for the quarter reached $27.11m , beating expectations by +50.42%.
Earnings released on 5 Mar 2025
EPS came in at -$0.31 falling short of the estimated $0.01 by -3.20k%, while revenue for the quarter reached $31.03m , beating expectations by +104.15%.
Earnings released on 31 Oct 2024
EPS came in at -$0.39 surpassing the estimated -$0.40 by +2.50%, while revenue for the quarter reached $16.00m , missing expectations by -66.01%.
Earnings released on 1 Aug 2024
EPS came in at -$0.49 falling short of the estimated -$0.42 by -17.37%, while revenue for the quarter reached $19.24m , beating expectations by +61.22%.
Earnings released on 2 May 2024
EPS came in at -$0.42 falling short of the estimated -$0.31 by -35.48%, while revenue for the quarter reached $10.03m , missing expectations by -42.74%.
Earnings released on 6 Mar 2024
EPS came in at -$0.20 surpassing the estimated -$0.39 by +48.72%, while revenue for the quarter reached $16.93m , missing expectations by -4.18%.
Earnings released on 7 Nov 2023
EPS came in at -$0.41 surpassing the estimated -$0.55 by +25.45%, while revenue for the quarter reached $16.51m , beating expectations by +12.80%.
Earnings released on 10 Aug 2023
EPS came in at -$0.76 falling short of the estimated -$0.51 by -49.02%, while revenue for the quarter reached $7.00m , missing expectations by -76.17%.
Earnings released on 8 May 2023
EPS came in at -$0.37 surpassing the estimated -$0.64 by +42.19%, while revenue for the quarter reached $35.58m , beating expectations by +83.07%.
Earnings released on 7 Mar 2023
EPS came in at $4.65 falling short of the estimated $4.84 by -3.93%, while revenue for the quarter reached $402.49m , beating expectations by +87.76%.
Earnings released on 8 Nov 2022
EPS came in at -$0.72 surpassing the estimated -$0.94 by +23.40%, while revenue for the quarter reached $2.63m , missing expectations by -33.18%.
Earnings released on 4 Aug 2022
EPS came in at -$0.97 falling short of the estimated -$0.93 by -4.30%, while revenue for the quarter reached $5.44m , missing expectations by -23.22%.
Earnings released on 4 May 2022
EPS came in at -$1.19 falling short of the estimated -$0.97 by -22.68%, while revenue for the quarter reached $1.92m .
Earnings released on 24 Feb 2022
EPS came in at -$0.95 surpassing the estimated -$1.06 by +10.38%, while revenue for the quarter reached $19.87m , beating expectations by +146.53%.
Earnings released on 3 Nov 2021
EPS came in at -$1.25 falling short of the estimated -$1.18 by -5.93%, while revenue for the quarter reached $4.40m , missing expectations by -43.29%.
Earnings released on 4 Aug 2021
EPS came in at -$1.31 falling short of the estimated -$1.06 by -23.58%, while revenue for the quarter reached $1.77m , missing expectations by -75.06%.
ZYME Stock Performance
Access detailed ZYME performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
